Advertisement

Advertisement

Solid Tumors
Immunotherapy

Response to Immune Checkpoint Inhibitors Not Affected by Age

Older patients with a solid tumor responded with similar clinical outcomes to younger patients treated with immune checkpoint inhibitors, the results of a study published in Nature Communications showed. However, older patients did have divergent immune phenotypes compared with younger patients,...

Hematologic Malignancies
Issues in Oncology
Immunotherapy

Role of Pathologists in Improving Access to Safer, More Effective Allogeneic Cell Therapies

Researchers are working to accelerate the clinical adoption of novel allogeneic cell therapies to improve cancer care and treatment, according to a new report from the College of American Pathologists (CAP). Background Allogeneic cell therapy—which uses cells from a healthy donor rather than a...

Lung Cancer
Immunotherapy

Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape over the last decade for patients with non–small cell lung cancer (NSCLC), the agents can also stimulate uncontrolled immunity against normal tissues and organs, leading to a cascade of immune-related adverse...

CNS Cancers
Skin Cancer
Lung Cancer
Immunotherapy

Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases

Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...

Lymphoma
Immunotherapy

NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma

A novel cell therapy approach using cord blood–derived natural killer (NK) cells precomplexed with the CD30/CD16A bispecific antibody AFM13 may be safe and generate responses in patients with refractory CD30-positive lymphomas, according to a recent study published by Nieto et al in Nature...

Bladder Cancer
Immunotherapy

Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper-Tract Urothelial Carcinoma

In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper tract urothelial carcinoma. Study Details In this multicenter open-label trial, 45...

Solid Tumors
Issues in Oncology
Immunotherapy

Parker Institute for Cancer Immunotherapy Names New CEO

The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as the new Chief Executive Officer (CEO) of the institute. A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen will take on her...

Head and Neck Cancer
Immunotherapy

Neoadjuvant Nivolumab Plus Chemotherapy and Response-Stratified CRT in HPV-Negative Head and Neck Cancer

In a single-center phase II trial (DEPEND) reported in JAMA Oncology, Rosenberg et al found that the combination of neoadjuvant nivolumab and chemotherapy followed by response-stratified chemoradiation (CRT) was active in human papillomavirus (HPV)-negative stage IVa/b head and neck squamous cell...

Pancreatic Cancer
Issues in Oncology
Genomics/Genetics
Immunotherapy

Race-Associated Molecular Differences and Treatment Response in Pancreatic Cancer

Investigators studied race-associated molecular differences in the pancreatic tumors of Black and White patients to determine whether such differences were associated with response to immunotherapy. The findings were published recently by Mandal et al in Cancer Research Communications and reinforce ...

Gynecologic Cancers
Issues in Oncology
Immunotherapy

BVAC-C Plus Durvalumab May Show Potential in Patients With Recurrent Cervical Cancer

A novel treatment approach may improve outcomes in patients with recurrent or metastatic cervical cancer, according to new findings presented by Choi et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer. Recurrent cervical cancer remains a significant challenge,...

Gynecologic Cancers
Issues in Oncology
Immunotherapy

Advances in Endometrial Cancer Detection, Treatment

Two novel studies may provide insights into advancements in the detection and treatment of endometrial cancer, according to new findings presented by Moore et al and Nolin et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer.  Together, the two studies...

Head and Neck Cancer
Immunotherapy

Neoadjuvant Combination Immunotherapy for Head and Neck Cancer

A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug, according to a recent study published by Li et al in Cancer Cell. Background Head and neck squamous cell carcinomas occur in the...

Head and Neck Cancer
Issues in Oncology
Immunotherapy

Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer

Combining the PD-1 inhibitor nivolumab and chemotherapy, and following that regimen with response-adapted chemoradiation, may an effective treatment for advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma, according to a recent study published by Rosenberg et al in...

Hepatobiliary Cancer
Immunotherapy

Outcomes After Complete Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma

In a retrospective study reported in JAMA Network Open, Lim et al found that complete response to immunotherapy as first-line treatment of advanced hepatocellular carcinoma was associated with good outcomes. Study Details The study involved analysis of 228 patients who received atezolizumab and...

Solid Tumors
Immunotherapy

Combination of Immunotherapies for Advanced HPV-Associated Cancers

In a single-center phase I/II trial reported in JAMA Oncology, Floudas et al found that the combination of the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin-12 antibody-drug conjugate PDS01ADC, and the bifunctional PD-L1/TGF-β inhibitor bintrafusp...

Solid Tumors
Immunotherapy

Novel Antibody-Toxin Conjugate Evaluated in Early Study

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published in Nature Cancer, the new approach combined the benefits of antibody-drug...

Supportive Care
Immunotherapy
Symptom Management
Issues in Oncology

Text Message Platform May to Help Address ‘Time Toxicity’ in Patients With Cancer

Digital technology may help to safely reduce the amount of time some patients with cancer spend receiving care—also referred to as “time toxicity”—according to a recent study published by Bange et al in NEJM Catalyst. Background Patients with cancer often spend a large amount of time on activities...

Lymphoma
Immunotherapy

Novel CD19-1XX CAR With Calibrated Signaling in LBCL

In a single-institution phase I study reported in the Journal of Clinical Oncology, Jae H. Park, MD, and colleagues found that first-in-human use of a CD19-1XX chimeric antigen receptor (CAR) T-cell therapy with calibrated signaling showed high activity in patients with relapsed or refractory large ...

Gynecologic Cancers
Immunotherapy

Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers

As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs). As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...

Kidney Cancer
Issues in Oncology
Immunotherapy

Safety of Ceasing Combination Therapy After 2 Years in Patients With Renal Cell Carcinoma

Ceasing or pausing a combination of the immune checkpoint inhibitor nivolumab and the oral tyrosine kinase inhibitor (TKI) axitinib after 2 years may be safe among patients with metastatic renal cell carcinoma who achieved a positive response to this treatment, according to updated analysis of a...

Immunotherapy
Issues in Oncology
Solid Tumors

Are Immune Checkpoint Inhibitors Effective in Hospitalized Patients With Cancer?

Immune checkpoint inhibitors may be ineffective among patients hospitalized with cancer, according to a recent study published by Riaz et al in JCO Oncology Practice. Background Immune checkpoint inhibitors have transformed treatment for many cancer types but are often restricted for inpatient use...

Gynecologic Cancers
Immunotherapy
Issues in Oncology

Flagellin and Immune Checkpoint Inhibition in Patients With Ovarian Cancer

The interference of gut bacteria could explain the ineffectiveness of immune checkpoint therapy in some patients with ovarian cancer, according to a recent study published by McGinty et al in Cancer Immunology Research.  Background There are over 10,000 ovarian cancer–related deaths in the United...

Solid Tumors
Issues in Oncology
Immunotherapy
Colorectal Cancer
Hepatobiliary Cancer
Gastrointestinal Cancer

Anticancer Drug Pharmacokinetics May Differ by Sex

Investigators may have uncovered notable pharmacokinetic differences between male and female patients in at least 14 anticancer drugs, according to a recent study published by Delahousse et al in ESMO Open. Background Many cancer drugs have a narrow therapeutic window. As a result, slight...

Solid Tumors
Issues in Oncology
Immunotherapy

Using AI to Identify Treatment Options for Castleman Disease

A novel artificial intelligence (AI) tool uncovered an effective treatment for a patient with idiopathic multicentric Castleman’s disease, according to a recent study published by Mumau et al in The New England Journal of Medicine. Background Idiopathic multicentric Castleman’s disease is a rare...

Kidney Cancer
Issues in Oncology
Immunotherapy

Novel Personalized Cancer Vaccine May Be Effective in Patients With Stage III and IV Clear Cell Renal Cell Carcinoma

Patients with stage III or IV clear cell renal cell carcinoma may have achieved a successful anticancer immune response following initiation of a novel personalized cancer vaccine, according to a recent study published by Braun et al in Nature. Background The standard treatment for stage III or IV...

Immunotherapy
Issues in Oncology
Hematologic Malignancies

CAR T-Cell Therapy Not Linked to Secondary Cancers, Study Finds

Researchers have found no evidence that chimeric antigen receptor (CAR) T-cell therapy caused secondary cancers in the modified T cells, according to a recent study published by Jadlowsky et al in Nature Medicine. Background CAR T-cell therapy is a personalized type of immunotherapy that employs...

Breast Cancer
Immunotherapy

Neoadjuvant Radiotherapy May Hamper Immunotherapy Response in Patients With Breast Cancer

Researchers have provided novel insights into the effects of radiation on the immune cells surrounding breast cancer tumors, according to a recent study published by Yoneyama et al in the International Journal of Radiation Oncology • Biology • Physics. The findings revealed that the relationship...

Leukemia
Immunotherapy
Issues in Oncology

Pinpointing Contributing Factors in Response to Posttransplant Donor Lymphocyte Infusion in Patients With AML

Researchers have identified factors that could determine whether donor lymphocyte infusion—a type of adoptive cell therapy—will result in remission among patients with acute myeloid leukemia (AML) who have relapsed following allogeneic hematopoietic stem cell transplant (HSCT), according to a...

Skin Cancer
Immunotherapy

Novel Tool for Predicting Response to Immunotherapy in Melanoma Under Study

A team of scientists from the United Kingdom and the United States has discovered that the activity of macrophages may prove to be useful in predicting whether or not a patient with melanoma will respond to immunotherapy. Their findings, published in JCO Oncology Advances, may help clinicians to...

Skin Cancer
Immunotherapy

Novel Combination Regimen May Prevent Squamous Cell Carcinoma

A recent study by Demehri et al of Mass General Brigham investigates whether calcipotriol—a vitamin D analog—plus fluorouracil may prevent squamous cell carcinoma (SCC), with benefits lasting 5 years after treatment. This combination therapy is the first to activate specific components of the...

Immunotherapy

Mesenchymal Cell Therapy Approved for Steroid-Refractory Acute GVHD

The U.S. Food and Drug Administration (FDA) recently approved remestemcel-L-rknd (Ryoncil), an allogeneic bone marrow–derived mesenchymal stromal cell therapy for steroid-refractory acute graft-vs-host disease (GVHD) in pediatric patients 2 months of age and older. The application received Orphan...

Hematologic Malignancies
Leukemia
Lymphoma
Immunotherapy
Issues in Oncology

Researchers May Have Uncovered Protein That Helps Cancer Cells Dodge CAR T-Cell Therapy

Researchers may have discovered a factor contributing to cancer cell evasion of chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Chen et al in Cell. The findings could lead to more personalized therapies that improve survival among patients with cancer....

Hepatobiliary Cancer
Immunotherapy
Issues in Oncology

Improving Hepatocellular Carcinoma Outcomes Through Enhanced Immunotherapy

A novel strategy may increase the activity of dendritic cells and improve immunotherapy outcomes in patients with hepatocellular carcinoma, according to a recent study published by Morita et al in Cancer Immunology Research. Background Hepatic cancer is a disease with a poor prognosis. Despite...

Leukemia
Immunotherapy
Issues in Oncology

Blinatumomab in Combination With Chemotherapy May Improve Survival in Pediatric Patients Newly Diagnosed With B-Cell Precursor ALL

The addition of blinatumomab to chemotherapy may improve disease-free survival in pediatric patients newly diagnosed with National Cancer Institute (NCI) standard-risk B-cell acute lymphoblastic leukemia (ALL) at average or high risk of relapse, according to new findings presented by Rau et al at...

Lymphoma
Immunotherapy

Preclinical Findings Show Ketogenic Diet Enhances CAR T-Cell Function, Improves Tumor Control

Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest that a ketogenic diet may enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy. The results point to β-hydroxybutyrate (BHB), a substance produced when a ketogenic diet is...

Immunotherapy
Lung Cancer

Metformin May Impact Immunotherapy in NSCLC

Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Journal of the National Cancer Institute.1 The investigators looked at data from two groups of...

Breast Cancer
Immunotherapy
Genomics/Genetics

Novel Immunotherapy May Offer Benefit in Early Clinical Trial for Breast Cancer

A novel cell-based immunotherapy may enhance treatment responses and reduce the need for conventional chemotherapy and its associated toxicities in patients with breast cancer, according to a recent study published by Han et al in JAMA Oncology. Study Methods and Results In the phase I clinical...

Breast Cancer
Immunotherapy

Updated Findings in Preventive Breast Cancer Vaccine Study

Researchers from Cleveland Clinic recently presented updated findings from a novel study of a vaccine aimed at preventing triple-negative breast cancer. The findings were presented at the Society for Immunotherapy of Cancer Annual Meeting.1 According to researchers, including principal...

Head and Neck Cancer
Immunotherapy

Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck Squamous Cell Carcinoma

  Alan Ho, MD, PhD, recently presented updated results from a phase II trial evaluating the combination of an HPV16-targeted investigational immunotherapeutic agent eseba-vec (previously known as HB-200) and the PD-1 inhibitor pembrolizumab as first-line therapy for human papillomavirus type 16...

Immunotherapy

Study Highlights From MD Anderson Researchers

Here are some highlights of clinical trials presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center. They include breakthroughs in cancer care, updates in clinical research, and efforts in cancer...

Immunotherapy
Issues in Oncology
Solid Tumors
CNS Cancers
Skin Cancer
Gynecologic Cancers

Challenges, Potential of Mesenchymal Stem Cells in Cancer Immunotherapy

Investigators have assessed the potential role of mesenchymal stem cells in cancer treatment in a new review published by Minev et al in Oncotarget. Study Overview and Implications The investigators found that mesenchymal stem cells can naturally target tumors and deliver therapeutic agents...

Immunotherapy
Issues in Oncology

Study May Illuminate Cause of Common Checkpoint Inhibitor Adverse Effect

Researchers may have uncovered the factors contributing to an increased susceptibility to common infections among patients with cancer receiving checkpoint inhibitors, according to a recent study published by Ogishi et al in Immunity. The findings may provide new insights into immune responses and...

Breast Cancer
Lung Cancer
Hepatobiliary Cancer
Gastroesophageal Cancer
Prostate Cancer
Skin Cancer
Immunotherapy

Highlights From the ESMO Congress 2024

The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highlighted the benefits of new combination immunotherapy strategies and innovative approaches in the...

Immunotherapy

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

In a retrospective cohort study reported in The Lancet Oncology, Sean Miller, MD, of Veterans Affairs Ann Arbor Healthcare System, and colleagues found that immune checkpoint inhibitor treatment for cancer had similar efficacy and reduced toxicity in Black patients vs White patients in the U.S....

Hematologic Malignancies
Solid Tumors
Immunotherapy
Genomics/Genetics
Issues in Oncology

New Technique May Allow for Visualization of CAR T Cells Postinjection

The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer. Background During...

Skin Cancer
Immunotherapy
Issues in Oncology

Immunotherapy Combination for Cutaneous Melanoma

Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings supported the development of vidutolimod for...

Bladder Cancer
Immunotherapy
Issues in Oncology

Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care

Recent advances in urothelial carcinoma treatments may offer a path to curative care for more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published by Milowsky in The New England Journal of Medicine. The findings indicated that...

Bladder Cancer
Prostate Cancer
Neuroendocrine Tumors
Immunotherapy

Pembrolizumab Plus Standard Chemotherapy May Benefit Patients With Rare, Aggressive Cancers

Researchers have found that combining the immunotherapy drug pembrolizumab with standard chemotherapy may improve treatment outcomes in patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer, according to a recent study published by Gu et al in Cell Reports Medicine....

Colorectal Cancer
Immunotherapy
Issues in Oncology

New Insights Into Innate Resistance for Immunotherapies in Colorectal Cancer

Researchers have assessed the efficacy of targeting the CD47 protein combined with traditional immunotherapy drugs in patients with colorectal cancer, with a recent study published by Arai et al in the Journal for ImmunoTherapy of Cancer. The findings indicated that the combination approach could...

Cardio-oncology
Immunotherapy

When Cancer and Cardiovascular Disease Intersect

The annual Global Cardio-Oncology Summit (GCOS) was held September 22 to 24 in Minneapolis, with 430 health-care professionals attending from 20 countries. The Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology...

Advertisement

Advertisement

Advertisement